300683 Stock Overview
A biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wuhan Hiteck Biological Pharma Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.16 |
| 52 Week High | CN¥37.48 |
| 52 Week Low | CN¥18.80 |
| Beta | -0.34 |
| 11 Month Change | -12.13% |
| 3 Month Change | -22.12% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300683 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.7% | -3.6% | -2.2% |
| 1Y | n/a | -23.4% | -17.9% |
Return vs Industry: Insufficient data to determine how 300683 performed against the CN Biotechs industry.
Return vs Market: Insufficient data to determine how 300683 performed against the CN Market.
Price Volatility
| 300683 volatility | |
|---|---|
| 300683 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300683's share price has been volatile over the past 3 months.
Volatility Over Time: 300683's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,520 | Ya Chen | www.hiteck.com.cn |
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit.
Wuhan Hiteck Biological Pharma Co.,Ltd Fundamentals Summary
| 300683 fundamental statistics | |
|---|---|
| Market cap | CN¥2.77b |
| Earnings (TTM) | -CN¥135.90m |
| Revenue (TTM) | CN¥595.54m |
4.7x
P/S Ratio-20.4x
P/E RatioIs 300683 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300683 income statement (TTM) | |
|---|---|
| Revenue | CN¥595.54m |
| Cost of Revenue | CN¥371.03m |
| Gross Profit | CN¥224.51m |
| Other Expenses | CN¥360.40m |
| Earnings | -CN¥135.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -1.04 |
| Gross Margin | 37.70% |
| Net Profit Margin | -22.82% |
| Debt/Equity Ratio | 2.1% |
How did 300683 perform over the long term?
See historical performance and comparison